Alzheimer’s disease can begin changing the brain years before a person or family notices anything unusual. That does not mean there is a simple set of hidden symptoms waiting to be recognized. It means the biology of Alzheimer’s, the biomarkers doctors can measure and the difficulties a person experiences do not necessarily appear at the same time.

This distinction matters because reports about Alzheimer’s research often move too quickly from changes found in brain tissue to advice about what families should watch for. A study may identify a vulnerable type of brain cell, but that does not automatically create a new symptom that can be recognized at home.

Memory problems remain one of the most common early signs of Alzheimer’s disease. However, memory is not always the first ability to change. Some people initially experience difficulty with language, judgment, navigation, visual processing, planning or familiar tasks. Personality and behavior can also change, but those changes have many possible explanations and cannot diagnose Alzheimer’s on their own.

The useful question is not simply, “Is this an early Alzheimer’s symptom?” It is, “Has something meaningfully changed from this person’s usual abilities, is it persisting, and is it beginning to affect everyday life?”

What the New Brain Research Actually Found

In 2024, researchers working with the Seattle Alzheimer’s Disease Brain Cell Atlas published a detailed analysis of brain tissue from 84 donors. The project examined cellular and molecular changes across different levels of Alzheimer’s disease severity.

The researchers found two broad patterns of disease progression.

During an earlier period, amyloid plaques and tau tangles accumulated relatively slowly. The researchers also observed immune activity, changes involving the protective insulation around nerve fibers and the loss of a particular type of inhibitory brain cell called a somatostatin-positive neuron.

These inhibitory neurons help regulate activity within brain circuits. Their early vulnerability was surprising because much Alzheimer’s research has focused on other cell types that are lost later in the disease.

A second period involved a much faster increase in Alzheimer’s pathology and more widespread loss of several types of neurons. This later pattern corresponded more closely with the cognitive decline commonly associated with the disease.

This research gives scientists a more detailed map of how Alzheimer’s may progress inside the brain. It may eventually help identify better treatment targets and better times to intervene.

It does not establish two clinical stages that families can identify by watching someone’s behavior. It also does not prove that the early loss of inhibitory neurons produces impulsivity, irritability or mood swings before memory changes appear.

The study examined brain tissue and reconstructed patterns of disease progression. It was not a clinical study showing that a particular behavior reliably predicts Alzheimer’s disease.

Brain Changes, Biomarkers and Symptoms Are Different Things

Alzheimer’s can be considered at three related but distinct levels.

The first level is what is happening biologically. Amyloid may accumulate, tau may spread, inflammation may increase and vulnerable brain cells may begin to malfunction or die.

The second level is what medical testing can detect. Depending on the circumstances, amyloid and tau may be assessed through specialized brain imaging, cerebrospinal fluid or blood-based biomarkers.

The third level is what the person experiences. This might include difficulty remembering recent events, finding words, managing finances, following familiar directions or making decisions.

These levels overlap, but they are not interchangeable. A person may have measurable Alzheimer’s-related changes without noticeable impairment. Someone else may have cognitive symptoms caused by a different medical condition. A biomarker can contribute important evidence, but it does not replace the person’s history, examination and overall clinical picture.

This is why neither a behavior checklist nor a laboratory result should be treated as a complete diagnosis.

What Changes May Deserve Attention?

A single lapse rarely tells us very much. Everyone occasionally loses a word, forgets why they entered a room or overlooks an appointment.

More concerning changes are usually persistent, represent a departure from the person’s previous abilities and begin interfering with familiar activities.

Difficulty retaining recent information

The person may repeatedly ask the same question, forget conversations that occurred recently or rely much more heavily on notes and reminders. The important difference is not occasional forgetfulness. It is that new information no longer seems to stay available in the way it once did.

Problems with planning and multistep tasks

A person who previously managed household finances may begin missing payments, entering the same transaction more than once or becoming confused by familiar statements. Cooking a well-known recipe, arranging travel or following a sequence of instructions may become unexpectedly difficult.

Changes in judgment

Uncharacteristic financial decisions, vulnerability to scams, unsafe driving choices or difficulty recognizing obvious risks may warrant attention. Judgment can be affected by many conditions, so the change needs to be considered in context.

Language difficulties

The person may struggle to retrieve common words, lose the thread of a conversation, substitute an unrelated word or have increasing difficulty understanding what others are saying.

Occasionally searching for a name is common. A progressive change that disrupts communication is different.

Disorientation or navigation problems

Getting lost in a familiar place, becoming confused about time or having trouble following a route used for years can be significant. Some forms of Alzheimer’s initially affect visual and spatial processing more than memory.

Withdrawal from familiar activities

A person may stop participating in conversations, hobbies or responsibilities because following them has become difficult. Withdrawal can also result from depression, hearing loss, fatigue, pain or social changes, which is why it should not be interpreted in isolation.

Personality or behavioral changes

Increased anxiety, suspiciousness, apathy, irritability, impulsivity or loss of social restraint can occur in dementia. These changes may sometimes appear early.

They are not specific to Alzheimer’s disease. Depression, grief, medication effects, sleep deprivation, alcohol use, pain, thyroid disorders and other neurological conditions can produce similar changes.

Behavior becomes more informative when it is clearly different from the person’s longstanding personality, continues over time and appears alongside changes in thinking or daily functioning.

The Pattern Matters More Than One Symptom

When families become concerned, they often search for one decisive sign. Alzheimer’s rarely announces itself so neatly.

A more useful approach is to look at four questions:

1. Is this a change from the person’s usual abilities? A lifelong tendency to misplace keys is different from a highly organized person suddenly losing important items repeatedly.
2. Is the change persistent or progressive? A difficult week during illness, grief or severe sleep loss is different from a decline continuing over several months.
3. Is more than one ability changing? Memory difficulty accompanied by navigation, language or judgment problems is more concerning than one isolated lapse.
4. Is it affecting everyday function? Trouble managing medication, finances, transportation, appointments or familiar household tasks deserves attention.
   
   

Specific examples are more useful to a clinician than saying, “Her memory seems worse.” Write down what happened, when it began, how often it occurs and whether anyone else observed it.

Many Conditions Can Resemble Cognitive Decline

An evaluation for memory or thinking changes is not simply a search for Alzheimer’s disease. It is also a search for other explanations, some of which may be treatable.

Possible contributors include:

• Medication side effects or interactions
• Depression, anxiety, grief or prolonged stress
• Sleep apnea and chronic sleep disruption
• Thyroid disorders
• Vitamin B12 deficiency
• Hearing or vision loss
• Alcohol or other substance use
• Infections or metabolic disturbances
• Stroke and vascular disease
• Head injury
• Other neurological conditions
  
  

More than one factor may be present. A person could have early Alzheimer’s changes and also have untreated sleep apnea, hearing loss or a medication burden that makes the cognitive difficulties worse.

That is another reason not to diagnose Alzheimer’s from behavior alone.

What an Evaluation May Include

A medical evaluation usually begins with the history of what has changed. Input from a family member or someone who knows the person well can be valuable, particularly when the person experiencing the changes does not recognize them.

The clinician may review:

• When the changes began and how they have progressed
• Medical and family history
• Prescription drugs, over-the-counter products and supplements
• Sleep, mood, hearing, vision and alcohol use
• Ability to manage everyday responsibilities
• Brief tests of memory, language, attention, reasoning and visual-spatial ability
• Blood tests for conditions that can affect cognition
• Brain imaging when appropriate
  
  

Specialists may use more extensive cognitive testing, amyloid PET imaging, cerebrospinal-fluid analysis or blood-based biomarkers.

In 2025, the FDA cleared the first blood test intended to help identify amyloid pathology in certain adults being evaluated for cognitive decline. It was an important development because blood testing may eventually make Alzheimer’s evaluation more accessible than relying primarily on specialized scans or spinal-fluid testing.

It is not a general screening test for people without symptoms, and it is not a stand-alone diagnosis. The result still has to be interpreted with the person’s symptoms, medical history and other clinical findings.

A positive Alzheimer’s biomarker shows evidence of disease-related biology. It does not explain every difficulty the person is experiencing, predict the exact rate of decline or determine the best treatment by itself.

Why Earlier Evaluation Can Matter

An early evaluation can identify treatable contributors, establish a baseline and give the person time to participate in decisions about healthcare, finances, living arrangements and support.

Earlier diagnosis may also affect treatment options.

Traditional Alzheimer’s medications, including donepezil, rivastigmine, galantamine and memantine, are used to help manage symptoms in appropriate patients. They do not remove the underlying disease.

Newer anti-amyloid treatments, including lecanemab and donanemab, are intended for carefully selected people with mild cognitive impairment or mild dementia caused by Alzheimer’s disease and confirmed amyloid pathology. These treatments can modestly slow decline for some eligible patients. They do not restore abilities that have already been lost or stop the disease completely.

They also carry meaningful risks, including amyloid-related imaging abnormalities, known as ARIA. These can involve brain swelling or bleeding and require clinical screening and MRI monitoring. Treatment decisions need to consider the expected benefit, health history, medications, genetic factors, monitoring requirements and the person’s priorities.

Earlier evaluation creates options. It does not guarantee that a disease-modifying treatment will be appropriate or effective.

When a Change Needs Immediate Attention

Alzheimer’s disease usually develops gradually. A sudden change in thinking, behavior or awareness should not be assumed to be dementia.

Abrupt confusion can be caused by infection, stroke, medication reactions, low blood sugar, dehydration, head injury or other urgent medical problems. Sudden weakness, facial drooping, difficulty speaking, severe headache, loss of balance or altered consciousness requires immediate medical attention.

The pace of change is an important clue. Gradual decline over months or years suggests a different process from confusion that appears over hours or days.

What Families Can Do Before an Appointment

If you are concerned about someone, collect observations without trying to prove a diagnosis.

Write down:

• Specific incidents and when they occurred
• Abilities that have changed
• Whether the problem is becoming more frequent
• Changes in medication, sleep, mood or health
• Any effects on driving, finances, cooking or medication management
• Questions the person and family want answered
  
  

Whenever possible, involve the person in the conversation. Concern about cognitive change can feel frightening and humiliating. Approaching the subject as a search for explanations is usually more constructive than announcing that someone “has dementia.”

The goal is not to attach a label as quickly as possible. It is to understand what has changed, determine what may be causing it and decide what should happen next.

Before Memory Loss Does Not Mean Before All Change

Alzheimer’s research is moving further into the period before obvious dementia. Scientists can now examine cellular changes, amyloid and tau biomarkers, and subtle cognitive patterns that were once invisible.

That progress is real, but it can create a misleading impression that Alzheimer’s can now be recognized from a few vague behavioral signs.

It cannot.

Behavioral and personality changes may be part of the picture, but they are not a private warning code for Alzheimer’s disease. The most useful signal is a persistent and meaningful change from the person’s previous abilities, especially when several areas of thinking or daily function are affected.

New tests can strengthen an evaluation. They do not replace the need to understand the person.